4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Genelux Corporation (GNLX) operates in the Biotechnology industry and is headquartered in Westlake Village, United States with about 25 employees. Its market capitalization is roughly $133 million. In the fiscal year ended 2025-12-31, GNLX reported $0M in revenue and ($32M) in net income.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Interactive charts & full statements → Open the GNLX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $11M | — |
| Operating Income (EBIT) | ($33M) | ($32M) | ($24M) | ($3M) | — |
| Net Income | ($32M) | ($30M) | ($28M) | ($5M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($9M) | ($9M) | ($8M) | ($8M) | ($8M) | — |
| Net Income | ($9M) | ($9M) | ($8M) | ($8M) | ($8M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $19M | $35M | $28M | $6M | — |
| Total Liabilities | $8M | $8M | $8M | $41M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GNLX viewer.
About TickerBase · Data methodology & sources